Scientists Demonstrate Pre-clinical Proof of Concept for Next-Gen DNA Delivery Technology
Findings show potential for new lipid-based delivery formulations as a platform technology for immunization
Philadelphia, PA, March 21, 2025 (GLOBE NEWSWIRE) -- Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., in collaboration with scientists in the laboratory of Norbert Pardi, Ph.D., at the University of Pennsylvania Perelman School of Medicine and at the Pennsylvania-headquartered biotechnology company INOVIO, described a next-generation vaccination technology that combines plasmid DNA with a lipid nanoparticle (LNP) delivery system. Their findings are published in Cell Reports Medicine in the paper, 'Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity.'David Weiner, Wistar executive vice president and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research, is a leading expert in the field of DNA vaccines. In the study led by Weiner lab doctoral student Nicholas Tursi, researchers aimed to study how to improve lipid-based formulations to better incorporate and deliver DNA payloads for immunization. Lipid-based approaches, including LNPs, have successfully formulated and delivered various forms of RNA as well as formulating proteins as drugs in several marketed products. However, developing such formulations using DNA has previously not shown the same stability or efficacy. Tursi et al. studied how to modify lipid-based formulations that would effectively stabilize DNA in LNPs, which would simplify their delivery and improve vaccine-induced immunity. DNA has unique properties relative to RNA, including its large size and double stranded nature, which has previously been a hurdle for creating stable and consistent lipid-based DNA formulations.DNA vaccines have been traditionally delivered using devices, which enable highly efficient uptake of DNA into cells at the injection site and potent T cell immunity against important disease targets. Utilizing an LNP formulation for DNA vaccines could potentially enable administration by needle and syringe and potentially enhance humoral immunity, which could provide an additional tool within the DNA vaccine toolkit.Using a model DNA-LNP expressing influenza hemagglutinin (HA), the team examined how to modulate the formulation of DNA within LNPs to improve particle assembly and stability for direct injection. HA DNA-LNPs formulated at higher N/P ratios—the relationship between the lipid nanoparticle and the larger DNA backbone—led to an improved particle profile, smaller particle size, with an improved generation of immune responses. The study highlights some of the mechanisms of immunity that are conferred by DNA-LNPs. The team showed that these DNA-LNPs demonstrate a unique way of priming the immune system compared to mRNA and protein-in-adjuvant formulations. The DNA-LNP induced a unique activation pattern of innate immune populations—cells that respond early in the development of a protective immune response. The team next examined whether HA DNA-LNPs could induce strong and consistent adaptive immunity—the arm of the immune system responsible for long lived T cell and antibody responses. Relative to benchmark mRNA and protein-in-adjuvant vaccines, HA DNA-LNPs induced robust antibody and T cell responses after a single dose. Importantly, these responses were durable, with memory responses in small animals persisting beyond a year after immunization. The team also examined the immunogenicity of HA DNA-LNPs in a rabbit model, where they observed strong T cell and antibody responses that persisted into the memory phase. Finally, the team examined whether DNA-LNP vaccines could be protective in a live SARS-CoV-2 challenge model. The team utilized a DNA-LNP vaccine expressing the SARS-CoV-2 spike protein and demonstrated that a single immunization with the spike DNA-LNP successfully prevented morbidity and mortality from challenge. This study supports the continued development DNA-LNP vaccines as a unique vaccination modality. The ability for this approach to trigger strong, long-lasting immune responses highlights its potential to complement existing approaches or be potentially developed as next-generation immunization platform.Authors: Nicholas J. Tursi1,2, Sachchidanand Tiwari3, Nicole Bedanova1, Toshitha Kannan1, Elizabeth Parzych1, Nisreen M.A. Okba4,5, Kevin Liaw1, András Sárközy3, Cory Livingston1, Maria Ibanez Trullen4,5, Ebony N. Gary1, Máté Vadovics3, Niklas Laenger1,6, Jennifer Londregan2, Mohammad Suhail Khan1, Serena Omo-Lamai7, Hiromi Muramatsu3, Kerry Blatney1, Casey Hojecki1, Viviane Machado8, Igor Marcic8, Trevor R.F. Smith8, Laurent M. Humeau8, Ami Patel1, Andrew Kossenkov1, Jacob S. Brenner7, David Allman2, Florian Krammer4,5,9,10, Norbert Pardi3,, and David B. Weiner1,
1Vaccine and Immunotherapy Center, The Wistar Institute2Perelman School of Medicine, University of Pennsylvania3Department of Microbiology, Perelman School of Medicine, University of Pennsylvania4Department of Microbiology, Icahn School of Medicine at Mount Sinai5Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai6Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania7Biology Department, Saint Joseph's University8INOVIO Pharmaceuticals9Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai10Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna
Work supported by: NIH grants R01AI146101, R01AI153064, and P01AI165066; NIH/NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051; and INOVIO Pharmaceuticals SRA 21-05. Additional funding provided by the W.W. Smith Charitable Trust Distinguished Professorship in Cancer Research and The Jill and Mark Fishman Foundation.
Publication information: 'Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity,' from Cell Reports Medicine
ABOUT THE WISTAR INSTITUTE
The Wistar Institute is the nation's first independent nonprofit institution devoted exclusively to foundational biomedical research and training. Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status. Through a culture and commitment to biomedical collaboration and innovation, Wistar science leads to breakthrough early-stage discoveries and life science sector start-ups. Wistar scientists are dedicated to solving some of the world's most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers. wistar.org.
CONTACT: Darien Sutton The Wistar Institute 215-870-2048 dsutton@wistar.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBS News
an hour ago
- CBS News
New text message scam claiming to be PennDOT puts drivers on alert, "Do not click on any of it."
Another day, another scam to be worried about, and once again, it's coming in by text message, claiming to be from PennDOT. The "warning" from the Pennsylvania Department of Motor Vehicles is dire: pay by today or else. "All of those texts are not from PennDOT, and they are a scam," said PennDOT's Aimee Inama. She said, despite the text message claiming that you have an outstanding ticket, and if you don't pay the balance, your vehicle registration will be suspended, your driver's license will be suspended for a month, and even more, know that PennDOT doesn't send texts about traffic violations or fines. Screenshot of the PennDOT text message scam KDKA So, if you get the text, drive happily on your way, and ignore the threat that you will be prosecuted. "Do not click on any of the links and just report it as spam," Inama said. "Just delete it, get rid of it, and just know that it didn't come from PennDOT." The text even claims that your credit score will be affected. While it sounds very intimidating and authentic, there is one tell above all to be on the lookout for showing that it's a scam. The message not only claims to be from PennDOT, the Pennsylvania Department of Transportation, but also the Commonwealth of Pennsylvania Department of Motor Vehicles. There is no such department in Pennsylvania. The closest thing is the PennDOT Division of Drivers and Vehicle Services. If you've received this message, you can report it to PennDOT on their website right here.
Yahoo
an hour ago
- Yahoo
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2025 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Links to each presentation are included below. 'We were pleased to present three encore presentations yesterday during the CMSC conference. We continue to be impressed by the BRIUMVI data and look forward to continuing to present updated data throughout the year.'TG PRESENTATIONS:Title: No Association between Decreases in Serum Immunoglobulin Levels and Serious Infections with Long-Term Ublituximab Treatment in Patients with Relapsing Multiple Sclerosis Presenting Author: Dr. Bruce Cree - Weill Institute for Neurosciences, University of California, San Francisco, CA Title: Retrospective Evaluation of Infusion Tolerability: Ublituximab Real-World Observational Survey (ENAMOR) Presenting Author: Dr. Edward Fox – TG Therapeutics - National Physician Liaison – VP, MS Global Operations Title: Safety and Tolerability of 30-Minute Ublituximab Infusions: Updates from the ENHANCE Study Presenting Author: Dr. John Foley – Rocky Mountain Multiple Sclerosis, Salt Lake City, Utah Following the presentations, the data presented will be available on the Publications page, located within the Pipeline section, of the Company's website at ABOUT THE ULTIMATE I & II PHASE 3 TRIALSULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four hours, 450 mg two weeks after the first infusion administered in one hour, and 450 mg every 24 weeks administered in one hour, with oral placebo administered daily; or teriflunomide, the active comparator, given orally as a 14 mg daily dose with IV placebo administered on the same schedule as BRIUMVI. Both studies enrolled patients who had experienced at least one relapse in the previous year, two relapses in the previous two years, or had the presence of a T1 gadolinium (Gd)-enhancing lesion in the previous year. Patients were also required to have an Expanded Disability Status Scale (EDSS) score from 0 to 5.5 at baseline. The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries. These trials were led by Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University. Additional information on these clinical trials can be found at (NCT03277261; NCT03277248). ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IVBRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses. BRIUMVI is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing- remitting disease, and active secondary progressive disease. A list of authorized specialty distributors can be found at IMPORTANT SAFETY INFORMATIONContraindications: BRIUMVI is contraindicated in patients with: Active Hepatitis B Virus infection A history of life-threatening infusion reaction to BRIUMVI WARNINGS AND PRECAUTIONS Infusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was 48%, with the highest incidence within 24 hours of the first infusion. 0.6% of BRIUMVI-treated patients experienced infusion reactions that were serious, some requiring hospitalization. Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment. Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was 56% compared to 54% in teriflunomide-treated patients. The rate of serious infections was 5% compared to 3% respectively. There were 3 infection-related deaths in BRIUMVI-treated patients. The most common infections in BRIUMVI- treated patients included upper respiratory tract infection (45%) and urinary tract infection (10%). Delay BRIUMVI administration in patients with an active infection until the infection is resolved. Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI. HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HB surface antigen (HBsAg) and anti-HB tests. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment. Although no cases of PML have occurred in BRIUMVI-treated MS patients, JCV infection resulting in PML has been observed in patients treated with other anti-CD20 antibodies and other MS therapies. If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis. If PML is confirmed, treatment with BRIUMVI should be discontinued. Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines at least 4 weeks and, whenever possible at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion. In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted. Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. A pregnancy test is recommended in females of reproductive potential prior to each infusion. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose. Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in 0.6% of BRIUMVI-treated patients compared to none of the patients treated with teriflunomide in RMS clinical trials. Monitor the levels of quantitative serum immunoglobulins during treatment, especially in patients with opportunistic or recurrent infections, and after discontinuation of therapy until B-cell repletion. Consider discontinuing BRIUMVI therapy if a patient with low immunoglobulins develops a serious opportunistic infection or recurrent infections, or if prolonged hypogammaglobulinemia requires treatment with intravenous immunoglobulins. Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least 10%) were infusion reactions and upper respiratory tract infections. Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit ABOUT BRIUMVI PATIENT SUPPORTBRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at ABOUT MULTIPLE SCLEROSISRelapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing- remitting multiple sclerosis (RRMS) and people with secondary progressive multiple sclerosis (SPMS) who continue to experience relapses. RRMS is the most common form of multiple sclerosis (MS) and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with MS in the United States and approximately 85% are initially diagnosed with RRMS.1,2 The majority of people who are diagnosed with RRMS will eventually transition to SPMS, in which they experience steadily worsening disability over time. Worldwide, more than 2.3 million people have a diagnosis of MS.1 ABOUT TG THERAPEUTICSTG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn. BRIUMVI® is a registered trademark of TG Therapeutics, Inc. Cautionary StatementThis press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below. Such forward looking statements include but are not limited to statements regarding the results of the ULTIMATE I & II Phase 3 studies, the ENHANCE Phase 3b study, and BRIUMVI as a treatment for relapsing forms of multiple sclerosis (RMS). Additional factors that could cause our actual results to differ materially include the following: the risk that the data from the ULTIMATE I & II or ENHANCE trials that we announce or publish may change, or the product profile of BRIUMVI may be impacted, as more data or additional endpoints are analyzed; the risk that data may emerge from future clinical studies or from adverse event reporting that may affect the safety and tolerability profile and commercial potential of BRIUMVI; the risk that any individual patient's clinical experience in the post-marketing setting, or the aggregate patient experience in the post-marketing setting, may differ from that demonstrated in controlled clinical trials such as ULTIMATE I and II; the risk that BRIUMVI will not be commercially successful; our ability to expand our commercial infrastructure, and successfully market and sell BRIUMVI in RMS; the Company's reliance on third parties for manufacturing, distribution and supply, and a range of other support functions for our commercial and clinical products, including BRIUMVI, and the ability of the Company and its manufacturers and suppliers to produce and deliver BRIUMVI to meet the market demand for BRIUMVI; the failure to obtain and maintain requisite regulatory approvals, including the risk that the Company fails to satisfy post-approval regulatory requirements; the uncertainties inherent in research and development; and general political, economic and business conditions. i Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our other filings with the U.S. Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. CONTACT: Investor RelationsEmail: ir@ (8489), Option 4 Media Relations:Email: media@ (8489), Option 6 1. MS Prevalence. National Multiple Sclerosis Society website: Accessed October 26, 2020. 2. Multiple Sclerosis International Federation, 2013 via Datamonitor in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Hola Prime Launches Performance Coaching Initiative to Tackle the #1 Barrier to Trader Success: The Mind
NEW YORK, NY, May 30, 2025 (GLOBE NEWSWIRE) -- In proprietary trading, success is often measured in percentages and profit curves. But behind every chart is a human being, and according to Hola Prime, one of the fastest-growing prop firms globally, that human element is the most overlooked edge in address this critical gap, Hola Prime has launched a new Performance Coaching Initiative, bringing psychological resilience, discipline, and emotional intelligence to the forefront of trader development. The firm has onboarded two accomplished professionals - Lara Leon and Stanislava Puac Jovanovic - and aims to solve what the firm calls "the #1 barrier to consistent trader performance: the mind." "We've funded traders all around the globe, and the pattern is clear - strategy alone doesn't make you consistent. Psychology does," said Somesh Kapuria, CEO of Hola Prime. "Our Performance Coaching Initiative is built to tackle that challenge head-on." Prop firms often compete on speed, funding, and payouts. But Hola Prime is betting that the next evolution of trading support won't be just financial - it will be behavioral. Whether it's FOMO, overtrading, revenge trading, or the inability to recover after a loss, psychological missteps are responsible for more failed trading careers than poor technical knowledge. Despite this, few firms invest in helping traders build emotional resilience, daily structure, and self-awareness. Hola Prime's new program is designed to fill that void, offering one-on-one performance coaching, guided psychological routines, and mindset-focused support for its funded traders. The goal is not short-term motivation, but long-term, measurable consistency. Globally Renowned Performance Coaches To drive the initiative, Hola Prime has onboarded: Lara Leon, a performance coach with over a decade of experience in psychology and active trading. A psychotherapist by training and a trader by passion, Lara blends cognitive insight with technical market expertise - covering order flow, volume profiles, and multi-timeframe analysis. Her coaching focuses on building internal discipline, trade journaling, and walking through emotional pitfalls with clarity and structure. Stanislava Puac Jovanovic, a psychologist and life coach with over 15 years of experience across education, coaching, and systemic psychotherapy. Certified in CBT, REBT, assertive communication, mindfulness, and NLP, she brings a holistic understanding of emotional regulation, stress management, and performance psychology - tools essential for thriving in high-pressure trading environments. Both coaches will offer traders structured frameworks to improve risk management, build sustainable habits, and enhance decision-making under stress. This initiative marks a shift in how prop firms support their traders - not just with capital, but with cognitive and emotional infrastructure. For Hola Prime, performance coaching is not an add-on - it's a foundational investment in trader longevity. At a time when retail traders face increased market volatility, higher expectations, and rapid information flow, support is more essential than ever. "The future of prop trading belongs to firms that understand one truth," said Kapuria. "The edge isn't just in the market. It's in the mind." Social Links Instagram: YouTube: LinkedIn: X: Discord: Quora: Reddit: Medium: Media Contact Company: Hola Prime Contact: Media Team Email: marketing@ Website: SOURCE: Hola PrimeError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
